Clinical Trials Logo

Clinical Trial Summary

The purpose of the trial is to evaluate efficacy and safety of QMF149 150/80 microgram o.d.

delivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler® in terms of lung function and symptom control in poorly (ie inadequately) controlled asthma patients. This study will assess contribution of LABA as an add-on therapy to low dose ICS monotherapy.


Clinical Trial Description

The primary objective of this study is to demonstrate the superiority of QMF149 150/80 microgram o.d. (in the evening) delivered via Concept1 compared with MF 200 microgram o.d. (in the evening) delivered via Twisthaler® in terms of trough FEV1 after 12 weeks of treatment in adults and adolescents. The key secondary objective of this study is to demonstrate the superiority of QMF149 150/80 microgram to MF 200 microgram o.d. in terms of ACQ-7 after 12 weeks of treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02892344
Study type Interventional
Source Novartis
Contact Novartis Pharmaceuticals
Phone +41613241111
Email trialandresults.registries@novartis.com
Status Recruiting
Phase Phase 3
Start date January 1, 2017
Completion date November 23, 2018

See also
  Status Clinical Trial Phase
Completed NCT00380354 - Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma Phase 2
Completed NCT00453778 - A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients Phase 4
Completed NCT00466596 - Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements Phase 1
Completed NCT00287365 - Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers N/A
Completed NCT00448851 - Study of Dust Mite Inhalation in Humans Phase 1
Completed NCT03421730 - A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma Phase 1